2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More)
Turning $1,000 into $2,400 in five years is no easy feat -- it requires a compound annual growth rate (CAGR) of 19.1%. However, both Regeneron (NASDAQ: REGN) and Moderna (NASDAQ: MRNA) have been able to pull that off (and then some) in the past half decade. Naturally, that doesn't automatically make these biotech stocks worth buying. Past performance isn't a guarantee of future success.
Can Regeneron and Moderna deliver similar returns in the next five years? Let's dig in and find out.
Source Fool.com
Regeneron Pharmaceuticals Inc. Stock
€874.20
-0.020%
The stock is one of the favorites of our community with 34 Buy predictions and 1 Sell predictions.
With a target price of 957 € there is a slightly positive potential of 9.47% for Regeneron Pharmaceuticals Inc. compared to the current price of 874.2 €.
